Additional file 1 of Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy

Additional file 1: Assessed AUCs of inflammation-based prognostic models and AFP to predict OS and DFS, and subgroups analyses of OS and DFS in different FAR risk groups based on these models

Average size of tumor prediction.

<p>Average size of tumor prediction.</p

RuCp* Complexes of Ambidentate 4,5-Diazafluorene Derivatives: From Linkage Isomers to Coordination-Driven Self-Assembly

The coordination chemistry of the {RuCp*}⁺ fragment was studied toward several 4,5-diazafluorene derivatives. The ambidentate nature of these 4,5-diazafluorene derivatives with multiple coordination sites allowed for the syntheses of different linkage isomers and self-assembled macrocycles. Both a tetramer (<b>2</b>) and a monomer (<b>3</b>) of [RuCp*<b>L</b>] (where <b>L</b>^<b>–</b> = 4,5-diazafluorenide) were prepared with the <b>L</b>^<b>–</b> ligand. The dimeric head-to-tail macrocycles [Cp*Ru­(L_pH)]₂Cl₂ (<b>4</b>) and [Cp*RuL_p]₂ (<b>5</b>) were obtained with the ditopic <b>L</b>_<b>p</b><b>H</b> and <b>L</b>_<b>p</b>^<b>–</b> ligands (where <b>L</b>_<b>p</b><b>H</b> = 9-(2-(diphenylphosphino)­ethyl)-4,5-diazafluorene and <b>L</b>_<b>p</b>^<b>–</b> = 9-(2-(diphenylphosphino)­ethyl)-4,5-diazafluorenide). The bulky arene-substituted <b>L</b>_<b>Mes</b><b>H</b> ligand (where <b>L</b>_<b>Mes</b><b>H</b> = 3,6-dimesityl-4,5-diazafluorene) was prepared, and its coordination to {RuCp*}⁺ gave [Cp*Ru­(<b>L</b>_<b>Mes</b><b>H</b>)]Cl (<b>13</b>). The selective syntheses of different linkage isomers of [RuCp*­(<b>L</b>_<b>Mes</b>)] (<b>14</b> and <b>15</b>) (where <b>L</b>_<b>Mes</b>^<b>–</b> = 3,6-dimesityl-4,5-diazafluorenide) were also demonstrated

Table2_Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer.XLS

Our study aimed to explore the effect of cellular senescence and to find potential therapeutic strategies for gastric cancer. Cellular senescence-related genes were acquired from the CellAge database, while gastric cancer data were obtained from GEO and TCGA databases. SMARCA4 had the highest mutation frequency (6%), and it was linked to higher overall survival (OS) and progression-free survival (PFS). The gastric cancer data in TCGA database served as a training set to construct a prognostic risk score signature, and GEO data were used as a testing set to validate the accuracy of the signature. Patients with the low-risk score group had a longer survival time, while the high-risk score group is the opposite. Patients with low-risk scores had higher immune infiltration and active immune-related pathways. The results of drug sensitivity analysis and the TIDE algorithm showed that the low-risk score group was more susceptible to chemotherapy and immunotherapy. Most patients with mutation genes had a lower risk score than the wild type. Therefore, the risk score signature with cellular senescence-related genes can predict gastric cancer prognosis and identify gastric cancer patients who are sensitive to chemotherapy and immunotherapy.</p

Table5_Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer.XLS

Our study aimed to explore the effect of cellular senescence and to find potential therapeutic strategies for gastric cancer. Cellular senescence-related genes were acquired from the CellAge database, while gastric cancer data were obtained from GEO and TCGA databases. SMARCA4 had the highest mutation frequency (6%), and it was linked to higher overall survival (OS) and progression-free survival (PFS). The gastric cancer data in TCGA database served as a training set to construct a prognostic risk score signature, and GEO data were used as a testing set to validate the accuracy of the signature. Patients with the low-risk score group had a longer survival time, while the high-risk score group is the opposite. Patients with low-risk scores had higher immune infiltration and active immune-related pathways. The results of drug sensitivity analysis and the TIDE algorithm showed that the low-risk score group was more susceptible to chemotherapy and immunotherapy. Most patients with mutation genes had a lower risk score than the wild type. Therefore, the risk score signature with cellular senescence-related genes can predict gastric cancer prognosis and identify gastric cancer patients who are sensitive to chemotherapy and immunotherapy.</p

Table1_Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer.DOCX

Our study aimed to explore the effect of cellular senescence and to find potential therapeutic strategies for gastric cancer. Cellular senescence-related genes were acquired from the CellAge database, while gastric cancer data were obtained from GEO and TCGA databases. SMARCA4 had the highest mutation frequency (6%), and it was linked to higher overall survival (OS) and progression-free survival (PFS). The gastric cancer data in TCGA database served as a training set to construct a prognostic risk score signature, and GEO data were used as a testing set to validate the accuracy of the signature. Patients with the low-risk score group had a longer survival time, while the high-risk score group is the opposite. Patients with low-risk scores had higher immune infiltration and active immune-related pathways. The results of drug sensitivity analysis and the TIDE algorithm showed that the low-risk score group was more susceptible to chemotherapy and immunotherapy. Most patients with mutation genes had a lower risk score than the wild type. Therefore, the risk score signature with cellular senescence-related genes can predict gastric cancer prognosis and identify gastric cancer patients who are sensitive to chemotherapy and immunotherapy.</p

Table6_Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer.DOCX

Our study aimed to explore the effect of cellular senescence and to find potential therapeutic strategies for gastric cancer. Cellular senescence-related genes were acquired from the CellAge database, while gastric cancer data were obtained from GEO and TCGA databases. SMARCA4 had the highest mutation frequency (6%), and it was linked to higher overall survival (OS) and progression-free survival (PFS). The gastric cancer data in TCGA database served as a training set to construct a prognostic risk score signature, and GEO data were used as a testing set to validate the accuracy of the signature. Patients with the low-risk score group had a longer survival time, while the high-risk score group is the opposite. Patients with low-risk scores had higher immune infiltration and active immune-related pathways. The results of drug sensitivity analysis and the TIDE algorithm showed that the low-risk score group was more susceptible to chemotherapy and immunotherapy. Most patients with mutation genes had a lower risk score than the wild type. Therefore, the risk score signature with cellular senescence-related genes can predict gastric cancer prognosis and identify gastric cancer patients who are sensitive to chemotherapy and immunotherapy.</p

Detection rates of RCC local advance or distant metastasis by location and clinic stage.

<p>Detection rates of RCC local advance or distant metastasis by location and clinic stage.</p

Average tumor size by year.

<p>Average tumor size by year.</p

The change trend in increase of case number by Fuhrman grade from 2005 to 2014.

<p>In this figure, the X-axis represents the year from 2005 to 2014; the Y-axis represents number of the case. I: representing Fuhrman grade I; II: representing Fuhrman grade II; III: representing Fuhrman grade III; and IV: representing Fuhrman grade IV.</p